JCP
HZNP

Jabre Capital Partners’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Jabre Capital Partners’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-405,000
Closed -$5.85M – 107
2016
Q1 		$5.85M Buy
405,000
+205,000
+103% +$3.59M 0.93% 38
2015
Q4 		$3.83M Buy
+200,000
New +$3.89M 0.62% 57

Other funds holding HZNP

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return

Jabre Capital Partners's HZNP Position: Q2 2016 in Review

Jabre Capital Partners sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q2 2016, closing a stake of 405,000 shares — an estimated $5.85M sold.

Jabre Capital Partners first reported a position in HZNP in Q4 2015 and held it in 2 quarters. The position peaked at $5.85M in Q1 2016. 198 funds tracked by Wall St. Rank hold HZNP as of Q2 2016.

  • Jabre Capital Partners reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q2 2016 after selling out during the quarter.
  • Jabre Capital Partners sold 405,000 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q2 2016, an estimated $5.85M.
  • Jabre Capital Partners first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2015 and held it in 2 quarters.
  • Jabre Capital Partners's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $5.85M in Q1 2016.
  • 198 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q2 2016.

Based on Jabre Capital Partners's 13F filing for Q2 2016, filed 15 Aug 2016.